• Diffuse Large B Cell Lymphoma

I am the Medical Director of the Immune Effector Cell Therapy Program at the Dana-Farber Cancer Institute, which houses the CAR T-cell program at Dana-Farber/Brigham and Women’s Hospital, among other cellular therapies. My area of clinical practice is in lymphoma, and my research interests and experience are in immunotherapies for the treatment of B-cell non-Hodgkin lymphoma. I am the principle investigator of several CAR T-cell studies at Dana-Farber, which incorporate immune profiling by CyTOF as well as by multi-plex immunohistochemistry, and genomic and transcriptional sequencing on patient samples. I was awarded the NCI Cancer Clinical Investigator Team Leadership Award to develop and grow a clinical and research enterprise in immune effector cell therapies for the treatment of cancer at Dana-Farber. In addition to CAR T-cell therapy studies, I am or have been the principle investigator of several investigator initiated studies involving immunotherapy for lymphomas, including immunotherapy combinations and the use of a yeast derived beta-glucan as an immune adjuvant to antibody therapy with rituximab. I completed a 2-year training program in clinical and translational investigation, earning an MMSc from Harvard Medical School. My leadership in cellular therapies, as well as my ability to move back and forth between our clinic and our basic science, immunology and pathology laboratories makes me uniquely positioned to address the unmet medical needs in CAR T-cell and other cellular therapies based on the identification of key mediators and mechanisms of toxicity and resistance.